<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01638117</url>
  </required_header>
  <id_info>
    <org_study_id>AP-TRPV1_PI-02</org_study_id>
    <nct_id>NCT01638117</nct_id>
  </id_info>
  <brief_title>Cumulative Irritation Test of PAC-14028 in Healthy Volunteers</brief_title>
  <official_title>Phase I Clinical Trial to Investigate the Cumulative Skin Irritation of PAC-14028 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amorepacific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amorepacific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the cumulative irritation potential of the products
      listed by the Sponsor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy, adult volunteers of either sex will be patched daily on his/her arm with multiple
      strengths of PAC-14028 cream, non-active comparator and an active comparator over the course
      of 21 consecutive days. Twenty-four hours after each application, the Finn-chamber patches
      will be removed and the site evaluated using a five-point scale for irritation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Irritation Score (5-point scale, 0-4)</measure>
    <time_frame>Daily for 21 days</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>PAC14028-Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PAC-14028 Cream Vehicle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAC14028-0.1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAC-14028 Cream 0.1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAC14028-0.3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAC-14028 Cream 0.3%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAC14028-1.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAC-14028 Cream 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sodium Lauryl Sulfate, 0.5%</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PAC14028-Vehicle</intervention_name>
    <description>PAC-14028 Cream Vehicle, Daily for up to 21 days</description>
    <arm_group_label>PAC14028-Vehicle</arm_group_label>
    <other_name>PAC-14208 cream vehicle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC14028-0.1</intervention_name>
    <description>PAC-14028 Cream, 0.1%, Daily for up to 21 days</description>
    <arm_group_label>PAC14028-0.1</arm_group_label>
    <other_name>PAC-14208 Cream 0.1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC14028-0.3</intervention_name>
    <description>PAC-14028 Cream, 0.3%, Daily for up to 21 days</description>
    <arm_group_label>PAC14028-0.3</arm_group_label>
    <other_name>PAC-14208 Cream 0.3%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAC14028-1.0</intervention_name>
    <description>PAC-14028 Cream, 1%, Daily for up to 21 days</description>
    <arm_group_label>PAC14028-1.0</arm_group_label>
    <other_name>PAC-14028 Cream 1.0%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline, Daily for up to 21 days</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.9% Sodium chloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Positive</intervention_name>
    <description>Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days</description>
    <arm_group_label>Positive control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers of either sex, at least 20 years to 59 Years.

          -  Females must be of non-childbearing potential (i.e., post-menopausal or surgically
             sterile). All females must submit to a urine pregnancy test and have a negative result
             at Day 1 and at the final study visit.

          -  Subjects may be of any skin type or race providing their degree of skin pigmentation
             does not interfere with readings of skin reactions.

          -  Who voluntarily decides study participation after receiving detailed explanation about
             the study and fully understanding it and who provides written consent for compliance
             with study requirement including proper contraception.

        Exclusion Criteria:

          -  Atopic dermatitis/eczema, psoriasis will be excluded. Any skin disease that would in
             any way confound interpretation of the study results.

          -  Asthma and chronic bronchitis will be excluded.

          -  Inability to evaluate the skin in and around the potential patch test sites on the arm
             due to erythema, eschar, excoriation, tattoos, scars, unevenness in skin tones, or
             other skin damage or abnormality.

          -  A history of sensitivity to any component of any of the formulations and the Finn
             chamber.

          -  Used systemic or topical corticosteroids or other immunosuppressive medications within
             1 weeks of the Day 1 visit.

          -  Used nonsteroidal anti-inflammatory medications within 2 weeks of the Day 1 visit.

          -  Received immunizations within 2 weeks of the Day 1 visit.

          -  Any major illness within 4 weeks of the Day 1 visit.

          -  Female who is pregnant, trying to become pregnant, or breast feeding

          -  Use of chronic medications (such as antihistamines, corticosteroids, analgesics and
             anti-inflammatories) for one week before and during the study.

          -  Currently using any medication that, in the opinion of the investigator, may affect
             the evaluation of the study product or place the subject at undue risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyu-Han Kim, M.D.,Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Seoul National University Hospital, Department of Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital, Department of Dermatology</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2012</study_first_submitted>
  <study_first_submitted_qc>July 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2012</study_first_posted>
  <last_update_submitted>January 19, 2014</last_update_submitted>
  <last_update_submitted_qc>January 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

